Arturo Molina
Director at Forma Therapeutics, Inc., Chief Medical Officer at Protagonist Therapeutics, Inc. since 2022, and President-Elect at Stanford Medical Alumni Association. Former positions include Senior ...
Model output · Signal date 2026-10-16
Protagonist Therapeutics, Inc (PTGX) Stock Forecast Oct. 16, 2026
Analysis updated on Oct. 16, 2026 (UTC) · Total · absolute moveSwitch to Alpha · Nasdaq
Rating · 90D
Total
90-day forecast
Sign up free to reveal
30-day forecast
Total
Rank in coverage
Middle 30%
of 5171 stocks scored
Rank correlation · 90D
-6.0%
Spearman, 357 dates
Market Cap
$8.84B
mid-cap · #36 of 60 peers
Summary
Protagonist Therapeutics, Inc (PTGX) stock forecast summary
On Oct. 16, 2026, PTGX is rated Neutral: its 90-day Total forecast sits in the middle 30% of the 5171 stocks scored that day.
Protagonist Therapeutics, Inc is a mid-cap company with a market capitalization of $8.84B. It ranks number 36 by market capitalization among the 60 Pharmaceutical Preparations issuers in our coverage with a current forecast.
For PTGX, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -6.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 24.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected absolute price move over the horizon, market included. This is the number a price target is built from. Ratings: strong buy ≥ +5.0%, buy ≥ +3.4%, sell < +1.8%, strong sell < +0.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, PTGX included.
Follow PTGX freePrice
PTGX price chart and AI forecast
Cross-section · 2026-10-16
How PTGX ranks among 5171 stocks
90D Total forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Fundamentals · 2026-06-30
Protagonist Therapeutics, Inc (PTGX) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Pharmaceutical Preparations peers listed below that report each metric.
Valuation & Market
| Metric | PTGX | Rank |
|---|---|---|
| Market Cap | $8.84B | 36/60 |
| P/E Ratio | 172.84x | 2/32 |
| P/B Ratio | 10.50x | 14/42 |
| EPS | $0.79 | – |
| Book Value/Share | $13.01 | – |
| Revenue/Share | $3.49 | – |
| FCF/Share | $2.02 | – |
Profitability & Margins
| Metric | PTGX | Rank |
|---|---|---|
| ROIC | 6.9% | 19/46 |
| Operating Margin | 25.9% | 11/39 |
| EBT Margin | 36.4% | 10/46 |
| Tax Rate | 1.7% | – |
Financial Health
| Metric | PTGX | Rank |
|---|---|---|
| Current Ratio | 21.71x | 7/59 |
| D/E Ratio | 0.05x | 42/48 |
| Financial Leverage | 1.05x | 42/48 |
| Working Capital | $770M | 36/59 |
Cash Flow
| Metric | PTGX | Rank |
|---|---|---|
| Operating Cash Flow | $131M | 32/59 |
| Free Cash Flow | $131M | 27/50 |
| Capital Spending | -$610K | 9/50 |
| OCF Growth YoY | 231.8% | 2/33 |
| FCF Growth YoY | 252.0% | 3/31 |
| FCF/Sales | 57.9% | 2/42 |
| CapEx/Sales | 0.3% | 36/42 |
Operational Efficiency
| Metric | PTGX | Rank |
|---|---|---|
| Asset Turnover | 0.25x | 34/40 |
| Fixed Assets Turnover | 65.3x | 11/41 |
Income Statement
| Metric | PTGX | Rank |
|---|---|---|
| Total Revenue | $226M | 43/46 |
| Operating Income | $58M | 27/51 |
| R&D Expense | $175M | 49/58 |
Dividend & Shareholder Information
| Metric | PTGX | Rank |
|---|---|---|
| Shares Outstanding | 65M | – |
| EPS Growth | -14.1% | 15/24 |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $807M | 91.2% of assets |
| Cash & Short-term Investments | $420M | 47.4% of assets |
| Total Liabilities | $44M | 5.0% of assets |
| Short-term Debt | $34M | 3.8% of assets |
Quarterly Financial Reports
PTGX quarterly financials and insider trading
Industry Peers · Pharmaceutical Preparations
Protagonist Therapeutics, Inc (PTGX) industry peers
Companies classified under the same SEC industry code as Protagonist Therapeutics, Inc (Pharmaceutical Preparations): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Total) | Market Cap |
|---|---|---|
| PTGX Protagonist Therapeutics, Inc | ▶ | $8.84B |
| LLY Eli Lilly & Co | ▼ | $1.18T |
| JNJ Johnson & Johnson | ▼ | $615.87B |
| ABBV Abbvie Inc. | ▼ | $504.46B |
| MRK Merck & Co., Inc. | ▶ | $360.08B |
| NVS Novartis Ag | ▼ | $287.41B |
| AZN Astrazeneca Plc | ▼ | $256.39B |
| ABT Abbott Laboratories | ▼ | $182.37B |
| NVO Novo Nordisk A S | ▼ | $172.56B |
| PFE Pfizer Inc | ▼ | $167.80B |
| VRTX Vertex Pharmaceuticals Inc / Ma | ▼ | $128.95B |
| BMY Bristol Myers Squibb Co | ▼ | $122.05B |
| GSK Gsk Plc | ▼ | $100.46B |
| SNY Sanofi | ▼ | $99.33B |
| REGN Regeneron Pharmaceuticals, Inc. | ▼ | $82.34B |
| TAK Takeda Pharmaceutical Co Ltd | ▼ | $60.76B |
| TEVA Teva Pharmaceutical Industries Ltd | ▼ | $47.91B |
| ONC Beone Medicines Ltd. | ▲ | $41.96B |
| ZTS Zoetis Inc. | ▼ | $32.40B |
| ALNY Alnylam Pharmaceuticals, Inc. | ▶ | $31.02B |
| RPRX Royalty Pharma Plc | ▶ | $26.29B |
| ROIV Roivant Sciences Ltd. | ▲ | $24.59B |
| GMAB Genmab A/S | ▶ | $23.80B |
| UTHR United Therapeutics Corp | ▼ | $23.23B |
| INSM Insmed Inc | ▶ | $21.02B |
| VTRS Viatris Inc | ▼ | $20.93B |
| ASND Ascendis Pharma A/S | ▶ | $14.85B |
| JAZZ Jazz Pharmaceuticals Plc | ▼ | $13.65B |
| BBIO Bridgebio Pharma, Inc. | ▶ | $12.98B |
| SMMT Summit Therapeutics Inc. | ▲ | $12.26B |
| CORT Corcept Therapeutics Inc | ▲ | $11.91B |
| ELAN Elanco Animal Health Inc | ▶ | $11.77B |
| RDY Dr Reddys Laboratories Ltd | ▼ | $10.77B |
| BMRN Biomarin Pharmaceutical Inc | ▶ | $10.58B |
| MDGL Madrigal Pharmaceuticals, Inc. | ▼ | $10.39B |
| TGTX Tg Therapeutics, Inc. | ▶ | $8.89B |
| CYTK Cytokinetics Inc | ▲ | $8.61B |
| AXSM Axsome Therapeutics, Inc. | ▲ | $8.23B |
| ARWR Arrowhead Pharmaceuticals, Inc. | ▲ | $7.90B |
| ABVX Abivax S.A. | ▼ | $7.74B |
| IONS Ionis Pharmaceuticals Inc | ▲ | $7.14B |
| SYRE Spyre Therapeutics, Inc. | ▲ | $7.06B |
| ALKS Alkermes Plc. | ▲ | $6.92B |
| PRAX Praxis Precision Medicines, Inc. | ▲ | $6.75B |
| KNSA Kiniksa Pharmaceuticals International, Plc | ▼ | $6.13B |
| AMRX Amneal Pharmaceuticals, Inc. | ▶ | $6.13B |
| RYTM Rhythm Pharmaceuticals, Inc. | ▶ | $6.06B |
| LGND Ligand Pharmaceuticals Inc | ▼ | $5.89B |
| BLTE Belite Bio, Inc | ▲ | $5.62B |
| MIRM Mirum Pharmaceuticals, Inc. | ▲ | $5.20B |
| COGT Cogent Biosciences, Inc. | ▲ | $5.12B |
| PTCT Ptc Therapeutics, Inc. | ▶ | $5.09B |
| ORKA Oruka Therapeutics, Inc. | ▲ | $4.76B |
| TVTX Travere Therapeutics, Inc. | ▲ | $4.72B |
| ERAS Erasca, Inc. | ▲ | $4.68B |
| MANE Veradermics, Inc | ▲ | $4.55B |
| EWTX Edgewise Therapeutics, Inc. | ▲ | $4.04B |
| DNTH Dianthus Therapeutics, Inc. /De/ | ▲ | $4.03B |
| INDV Indivior Pharmaceuticals, Inc. | ▼ | $3.83B |
| TNGX Tango Therapeutics, Inc. | ▲ | $3.83B |
Where PTGX sits on the market map
Life Sciences · Pharmaceutical Preparations
News
Protagonist Therapeutics, Inc (PTGX) stock news
UBS initiates coverage of Protagonist Therapeutics with buy rating
Fintel reports that on October 12, 2026, UBS initiated coverage of Protagonist Therapeutics (NASDAQGM:PTGX) with a Buy recommendation. Protagonist Therapeutics, Inc., based in the United States, ...
Protagonist Therapeutics, Inc. (PTGX) Discusses FDA Approval of Mimrylo for Erythrocytosis in Polycythemia Vera Transcript
Welcome to the Protagonist Therapeutics conference call. [Operator Instructions] As a reminder, this call is being recorded today, Monday, August 31, 2026. I'll now turn the call over to Dr. Corey ...
FAQ
Protagonist Therapeutics, Inc (PTGX) stock forecast FAQ
What is the Protagonist Therapeutics, Inc (PTGX) stock forecast?
On Oct. 16, 2026, PTGX is rated Neutral: its 90-day Total forecast sits in the middle 30% of the 5171 stocks scored that day.
How accurate are Protagonist Therapeutics, Inc stock predictions?
For PTGX, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -6.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 24.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Protagonist Therapeutics, Inc forecasts updated?
Protagonist Therapeutics, Inc forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.
Which companies are Protagonist Therapeutics, Inc's industry peers?
60 issuers in our coverage, PTGX included, share the SEC industry code Pharmaceutical Preparations. The largest are: Eli Lilly & Co (LLY), Johnson & Johnson (JNJ), Abbvie Inc. (ABBV), Merck & Co., Inc. (MRK), Novartis Ag (NVS), Astrazeneca Plc (AZN).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.